Wall Street brokerages forecast that Corium International Inc (NASDAQ:CORI) will post earnings of ($0.33) per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Corium International’s earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.29). Corium International reported earnings of ($0.36) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3%. The firm is expected to report its next earnings results on Thursday, November 15th.

On average, analysts expect that Corium International will report full-year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.56) to ($1.50). For the next year, analysts anticipate that the company will post earnings of ($1.42) per share, with EPS estimates ranging from ($1.73) to ($1.10). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Corium International.

Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $6.72 million. Corium International had a negative return on equity of 298.48% and a negative net margin of 155.21%.

Several research firms have commented on CORI. Zacks Investment Research raised Corium International from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Corium International in a research report on Monday, August 13th. ValuEngine upgraded Corium International from a “hold” rating to a “buy” rating in a research note on Friday, August 10th. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 target price on shares of Corium International in a research note on Friday, August 10th. Finally, BidaskClub upgraded Corium International from a “strong sell” rating to a “sell” rating in a research note on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.80.

CORI opened at $8.93 on Wednesday. The company has a market cap of $313.50 million, a price-to-earnings ratio of -5.46 and a beta of 1.45. Corium International has a 52 week low of $7.17 and a 52 week high of $13.93. The company has a current ratio of 8.11, a quick ratio of 7.95 and a debt-to-equity ratio of 1.89.

In related news, CEO Peter D. Staple sold 76,341 shares of Corium International stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $8.81, for a total value of $672,564.21. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert Thomas sold 35,608 shares of Corium International stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $8.86, for a total value of $315,486.88. Following the completion of the sale, the director now owns 35,608 shares in the company, valued at $315,486.88. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 119,965 shares of company stock worth $1,060,275. Company insiders own 30.80% of the company’s stock.

Several institutional investors have recently bought and sold shares of CORI. Franklin Resources Inc. boosted its stake in shares of Corium International by 115.3% in the first quarter. Franklin Resources Inc. now owns 2,059,175 shares of the biopharmaceutical company’s stock valued at $23,618,000 after buying an additional 1,102,910 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Corium International by 42.1% in the fourth quarter. BlackRock Inc. now owns 1,679,815 shares of the biopharmaceutical company’s stock valued at $16,143,000 after buying an additional 497,615 shares in the last quarter. Royce & Associates LP boosted its stake in shares of Corium International by 99.2% in the second quarter. Royce & Associates LP now owns 502,564 shares of the biopharmaceutical company’s stock valued at $4,026,000 after buying an additional 250,300 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Corium International by 127.9% in the first quarter. Candriam Luxembourg S.C.A. now owns 196,000 shares of the biopharmaceutical company’s stock valued at $2,248,000 after buying an additional 110,000 shares in the last quarter. Finally, Tamarack Advisers LP boosted its position in Corium International by 9.4% during the first quarter. Tamarack Advisers LP now owns 1,105,000 shares of the biopharmaceutical company’s stock worth $12,674,000 after purchasing an additional 95,000 shares in the last quarter. Hedge funds and other institutional investors own 95.26% of the company’s stock.

Corium International Company Profile

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

See Also: Asset Allocation

Get a free copy of the Zacks research report on Corium International (CORI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.